ImpediMed Limited is a world leader in the development and distribution of medical devices using Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of human disorders and diseases.
ImpediMed’s primary product range consists of a number of medical devices that enable surgeons, oncologists, radiation oncologists and therapists to clinically assess secondary lymphedema in breast cancer survivors. Pre-operative assessment can assist medical professionals to diagnose Lymphedema before the onset of symptoms and potentially before the condition progresses to irreversible forms. Irreversible Lymphedema becomes a lifelong management for patients and impairs their quality of life.
ImpediMed has the first medical devices with an FDA clearance in the United States for aiding in the clinical assessment, by health care providers, of unilateral lymphedema of the arm in women and the leg in women and men.